Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 4/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | CCR1 | P32246 | 1/20 | 0.52 |
| ▸ | CCR8 | P51685 | 1/20 | 0.52 |
| ▸ | MPL | P40238 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30693366 | 1.00 | TGFBR1 (0.53) | TGFBR1MAPK14CCR1CCR8MPL | |
| SCHEMBL20641330 | 0.83 | MPL (0.51) | TGFBR1MAPK14MPLSMN1; SMN2CD274 | |
| SCHEMBL30693356 | 0.83 | MPL (0.51) | TGFBR1MAPK14MPLSMN1; SMN2CD274 | |
| SCHEMBL19638056 | 0.79 | TGFBR1 (0.48) | TGFBR1MAPK14CCR1CCR8SMN1; SMN2 | |
| SCHEMBL11796387 | 0.77 | TGFBR1 (0.56) | TGFBR1CCR1CCR8SMN1; SMN2KDM4E | |
| Bromide SCHEMBL29078717 | 0.76 | TGFBR1 (0.54) | TGFBR1CCR1CCR8SMN1; SMN2KDM4E | |
| SCHEMBL924763 | 0.75 | TGFBR1 (0.53) | TGFBR1MAPK14CCR1CCR8SMN1; SMN2 | |
| SCHEMBL27843646 | 0.73 | NOS1 (0.62) | MPLSMN1; SMN2CD274NOS1FBP1 | |
| SCHEMBL330423 | 0.72 | SMN1; SMN2 (0.64) | MPLSMN1; SMN2CD274ALDH1A1KDM4E | |
| SCHEMBL3151901 | 0.72 | CCR1 (0.58) | TGFBR1MAPK14CCR1CCR8NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110869360-B | Phenylacetamides as ROCK inhibitors | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-3652164-B1 | PHENYLACETAMIDES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2023-06-21 | — | — | EP | disclosed |
| US-11306081-B2 | Phenylacetamides as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210147407-A1 | PHENYLACETAMIDES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | disclosed |
| EP-3652164-A1 | PHENYLACETAMIDES AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2020-05-20 | — | — | EP | disclosed |
| CN-110869360-A | Phenylacetamides as ROCK inhibitors | 百时美施贵宝公司 | 2020-03-06 | — | — | CN | disclosed |
| WO-2019014300-A1 | PHENYLACETAMIDES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147407-A1 | PHENYLACETAMIDES AS INHIBITORS OF ROCK | MYLK, ROCK1, ROCK2 | TGFBR1 200/4885MAPK14 93/4885CCR1 2497/4885 |
| US-11306081-B2 | Phenylacetamides as inhibitors of rock | MYLK, ROCK1, ROCK2 | TGFBR1 200/4885MAPK14 93/4885CCR1 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.